



Astal Laboratories Limited

(Formerly known as Macro International Limited)

Date: 24/05/2024

To,  
The Deputy Manager  
(Department of Corporate Services)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai- 400001  
Scrip Code: 512600  
Security Id: MACINTR

**Subject: Outcome of Board Meeting held on Friday, 24<sup>th</sup> May, 2024.**

Dear Sir/Madam,

This is to inform that Board of Directors of the Company in its meeting held on 24<sup>th</sup> May, 2024 at the corporate office of the company i.e. 304, 3rd Floor Babukhan Estate, Basheerbagh, Hyderabad Telangana 500001, which commenced at 5:00 P.M. has taken following decisions:

1. Considered and Approved the Audited Standalone Financial Results of the company for the quarter and financial year ended 31st March, 2024 along with the report of the auditors thereon.
2. Considered and Approved the Audited Standalone Financial Statements of the company for the quarter and financial year ended 31st March, 2024 along with the report of the auditors thereon.
3. Considered and approved the appointment of M/s **V R P S & Co.** Chartered Accountants (**FRN: 006340S**) as Internal Auditors for the F.Y. 2024-25.
4. Considered and approved the appointment of M/s Mahendra Khandelwal & Co. as Secretarial Auditor for the F.Y. 2024-25.
5. Considered and approved the Appointment of Mr. BIRENDRAKUMAR SAHOO (DIN: 06737993) as additional Independent Non-Executive Director of the Company.
6. Considered and approved to Keep & Maintain books of account at a place other than the registered office of the Company at 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034
7. Considered and approved to Shift the corporate office of the Company at 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034







Astal Laboratories Limited

(Formerly known as Macro International Limited)

---

The Meeting was concluded at 07:45 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Yours sincerely,

**For ASTAL LABORATORIES LIMITED**

**CIN: L74120UP1993PLC015605**

*mahendra*  
**MAHENDRA KUMAR**  
**(Company Secretary & Compliance Officer)**  
**Membership No. A71224**



Encl: as above



Annexure A

Details of Mr. Birendrakumar Sahoo as required under Para A (7) of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoDI/P/CIR/2023/123 dated 13th July, 2023:

Sr. No.	Details of Events that need to be provided	Information of such event(s)
1	Reason for change VIZ. Appointment, resignation, cessation, removal, death or otherwise	Appointment – Additional Non-executive Independent Director
2	Date of Appointment	24-05-2024
3	Brief profile (in case of appointment)	Mr. Birendrakumar Sahoo is a postgraduate in medicine who has been working in translational medical research. Dr. Birendrakumar Sahoo spent two decades in top management positions in global organizations like Terumo Corporation, Japan; Welch Allyn Inc, USA. He has travelled widely and lectured on research methodologies around the world. He has been a part of several leading research projects. Besides, he also set up telemedicine center as a part of South Asia Regional Cooperation project in Bhutan and also piloted the connected primary healthcare project in African countries. Dr. Birendrakumar Sahoo continues to be in research and teaching besides his practice as an internist.
4	Disclosure of relationships between directors (in case of appointment of a director)	No





Astal Laboratories Limited

(Formerly known as Macro International Limited)

Date: 24/05/2024

To,  
The Deputy Manager  
(Department of Corporate Services)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai- 400001  
Scrip Code: 512600  
Security Id: MACINTR

**Subject: Declaration regarding Audit Report with Un-Modified Opinion**

Dear Sir/ Ma'am,

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended by the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, it is hereby declared and confirmed that Auditors' Report obtained from M/s **SATHULURI & Co. Chartered Accountants (FRN: 006383S)** on Annual Audited Financial Results for the financial year ended on 31<sup>st</sup> March, 2024 has an unmodified opinion.

You are requested to take the above information on record.

Yours faithfully

**For ASTAL LABORATORIES LIMITED**

**CIN: L74120UP1993PLC015605**



**SUDHEER KARNA KANKANA**

**(Whole Time Director)**

**DIN: 07591466**





**Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of ASTAL LABORATORIES LIMITED Formerly Known as MACRO INTERNATIONAL LIMITED Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To

**The Board of Directors of**

**ASTAL LABORATORIES LIMITED**

**Formerly Known as MACRO INTERNATIONAL LIMITED**

'PLAZA KALPANA', GROUND FLOOR,

24/147, BIRHANA ROAD, KANPUR

Kanpur UP 208001 IN

Report on the audit of Financial Results

**Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of **ASTAL LABORATORIES LIMITED Formerly Known as MACRO INTERNATIONAL LIMITED**(the "Company") for the quarter ended March 31, 2024 and for the year ended March 31, 2024 ("Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive profit and other financial information of the Company for the quarter ended March 31, 2024 and for the year ended March 31, 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion



## **Management's Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net loss and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has



adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and based-on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review as required under the Listing Regulations.

#### **For Sathuluri & Co**

Chartered Accountants

Firm Reg No.006383S

SURYA PRAKASH Digitally signed by  
SATHULURI SURYA PRAKASH  
SATHULURI SATHULURI

**(S.S.Prakash)**

Partner

Membership No.202710

UDIN : **24202710BKELYL3673**

Place: Hyderabad

Date: 24-05-2024





Astral Laboratories Limited

(Formerly known as Macro International Limited)

Statement of Audited Financial Results for the quarter and year ended 31st March, 2024						
(Rs. In Lakhs except Earnings per share)						
S. No	Particulars	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for Previous year ended
		31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)	31.03.2023 (Audited)
1	<b>Revenue</b>					
	a) From operations	1,225.21	841.23	342.81	2,364.77	342.81
	b) Other Income (Refer to Note No.3)	0.04	-	9.43	1.34	17.87
	<b>Total Revenue</b>	<b>1,225.25</b>	<b>841.23</b>	<b>352.24</b>	<b>2,366.11</b>	<b>360.68</b>
2	<b>Expenses</b>					
	(a) Cost of Material Consumed	-	-	-	-	-
	(b) Purchases of stock-in-trade	1,180.98	769.87	335.46	2,239.64	335.46
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(105.76)	-	-	(105.76)	-
	(d) Employees Benefits expenses	39.00	4.74	3.14	46.57	6.48
	(e) Finance Cost	-	-	-	-	-
	(f) Depreciation amortization expenses	2.00	0.75	0.43	2.95	0.79
	(g) Other Expenses	53.21	17.14	2.03	74.05	14.74
	<b>Total Expenses</b>	<b>1,169.43</b>	<b>792.50</b>	<b>341.06</b>	<b>2,257.45</b>	<b>357.47</b>
3	<b>Profit from ordinary activities before exceptional Items (1 - 2)</b>	55.82	48.73	11.18	108.66	3.21
4	<b>Exceptional Items - Income/ (Expenses)</b>	-	-	-	-	-
5	<b>Profit from ordinary activities before tax (3 - 4)</b>	55.82	48.73	11.18	108.66	3.21
6	<b>Tax Expenses</b>					
	(a) Current Tax			0.97	29.37	0.96
	(b) Deferred Tax			(0.60)	0.82	(0.60)
7	<b>Profit/(Loss) for</b>	55.82	48.73	9.61	78.47	1.64

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India

Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India

Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIIP CODE: 512600, SECURITY ID: MACINTR, BSE India

Email: mail100@rediffmail.com; Website: <https://www.astral-lab.com>

8x





**Astal Laboratories Limited**  
(Formerly known as Macro International Limited)

<b>the period (5 -6)</b>						
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	
	B (i) Items that will not be reclassified to profit or loss (net of tax)					
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	
9	Total Comprehensive Income, net of tax (7 + 8)	55.82	48.73	9.61	78.47	1.64
10	Paid up equity share capital (Face Value of Rs.10/- each)	<b>984.56</b>	<b>493.96</b>	<b>389.96</b>	<b>984.56</b>	<b>398.96</b>
11	Earnings per share (of Rs.10/-each) not annualized					
	(a) Basic	<b>1.105</b>	<b>1.015</b>	<b>0.060</b>	<b>1.554</b>	<b>0.041</b>
	(b) Diluted	<b>1.105</b>	<b>1.015</b>	<b>0.060</b>	<b>1.554</b>	<b>0.041</b>

**See accompanying notes to financial results**

**NOTES:**

1	The above audited Financial Results of the company for the quarter ended March 31st, 2024 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on May 24, 2024.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India  
Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India  
Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIP CODE: 512600, SECURITY ID: MACINTR, BSE India  
Email: [meil100@rediffmail.com](mailto:meil100@rediffmail.com); Website: <http://astal.co.in/>







Astal Laboratories Limited

(Formerly known as Macro International Limited)

quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.

For ASTAL LABORATORIES LIMITED



SUDHEER KARNA KANKANALA

(Whole time Director)

DIN: 07591466

Date: 24/05/2024

Place: Hyderabad



Astal Laboratories Limited

(Formerly known as Macro International Limited)

**STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2024**

PARTICULARS		(Rs. In lakhs.)	
		As at 31-March 2024 (Audited)	As at 31-March 2023 (Audited)
<b>ASSETS</b>			
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	69.00	0.56
(b)	Capital work in progress	-	-
(c)	Investment property	-	-
(d)	Intangible assets	-	-
(e)	Financial assets	-	-
	(i) Investments	-	-
	(ii) Loans	399.25	378.75
	(iii) Other financial assets	-	-
(f)	Deferred tax Assets (Net)	-	0.11
(g)	Other non-current assets	520.26	-
	<b>Total non-current assets</b>	<b>988.51</b>	<b>379.43</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	105.76	-
(b)	<b>Financial assets</b>		
	(i) Investments	-	-
	(ii) Trade receivables	1,581.50	316.51
	(iii) Cash and cash equivalents	607.65	8.44
	(iv) Other balances with banks	-	-
	(v) Loans	-	-
	(vi) Other financial assets	-	-
(c)	Other Current assets	377.91	286.42
	<b>Total current assets</b>	<b>2,672.82</b>	<b>611.37</b>
	<b>TOTAL ASSETS</b>	<b>3,661.33</b>	<b>990.80</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Equity</b>		
(a)	Share capital	984.56	398.96

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India

Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India

Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIIP CODE: 512600, SECURITY ID: MACINTR, BSE India

Email: meil100@rediffmail.com: Website: <http://www.astal.com>







Astal Laboratories Limited

(Formerly known as Macro International Limited)

(b)	Other equity	1,349.39	118.72
	<b>Total Equity</b>	<b>2,333.95</b>	<b>517.68</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities		
	(i) Long-term borrowings	25.74	-
	(ii) Deferred tax liabilities (net)	0.72	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>26.46</b>	<b>-</b>
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities		
	(i) Borrowings	5.48	-
	(ii) Trade payables	1,151.51	379.29
	(iii) Other financial liabilities	100.00	70.00
(b)	Provisions		
(c)	Other current Liabilities	43.94	23.83
	<b>Total current liabilities</b>	<b>1,300.93</b>	<b>473.12</b>
	<b>Total Liabilities</b>	<b>1,327.39</b>	<b>473.12</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3,661.33</b>	<b>990.80</b>

By order of the Board  
For ASTAL LABORATORIES LIMITED



SUDHEER KARNA KANKANALA

Whole Time Director

DIN: 07591466

PLACE: Hyderabad

DATE: 24/05/2024



Astal Laboratories Limited  
(Formerly known as Macro International Limited)

AUDITED STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31 MARCH 2024

(Rs. in Lakhs)

PARTICULARS	As at 31-March -2024	As at 31-March -2023
	(Audited)	(Audited)
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>Profit before tax for the year</b>		
Net Profit before exceptional and tax as Statement Profit & Loss (Increase in Reserves)	108.66	3.21
Adjusted for: -		
Finance Cost	-	-
Depreciation and amortization	2.95	0.79
Bad debts written off	-	-
Loss on sale/ scrapping of Property, Plant and Equipment	-	-
Finance Cost	-	-
Interest income	(1.34)	(17.87)
<b>Operating Profit before Working Capital Changes</b>	110.27	(13.87)
Adjusted for changes in working capital	-	-
Increase / (Decrease) in Trade Payables	772.22	379.29
Increase / (Decrease) in Borrowings	-	-
Increase / (Decrease) in Other financial liabilities	-	-
Increase / (Decrease) in Other current liabilities	-	-
Increase / (Decrease) in Other Non-current liabilities	-	-
Increase / (Decrease) in Provisions (except IT)	-	-
Increase / (Decrease) in Current Tax Liabilities (Net)	23.74	86.95
(Increase)/Decrease in Inventory	(105.76)	-
(Increase)/Decrease in Trade receivables	(1,264.99)	(316.51)

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India  
Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India  
Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIP CODE: 512600, SECURITY ID: MACINTR, BSE India  
Email: meil100@rediffmail.com: Website: <https://www.astallab.com>







Astal Laboratories Limited  
(Formerly known as Macro International Limited)

	(Increase)/Decrease in Others current financial assets	-	-
	(Increase)/Decrease in Other current assets	(91.49)	(278.56)
	(Increase) / Decrease in Non-current Financial Assets	-	-
	<b>Cash Generated from Operations</b>	<b>(556.01)</b>	<b>(142.71)</b>
	<b>Net Cash used in Operating Activities Before Extraordinary Items</b>	<b>(556.01)</b>	<b>(142.71)</b>
	Less: - Extraordinary Items	-	-
	<b>Cash Generated from Operations</b>	<b>(556.01)</b>	<b>(142.71)</b>
	Less: - Taxes Paid	(3.00)	(0.96)
	<b>Net Cash Flow/(used) From Operating Activities (A)</b>	<b>(559.01)</b>	<b>(143.67)</b>
<b>B)</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	(Increase) / Decrease in Long Term Loans & Advances	(20.50)	132.40
	Purchase of Fixed Assets	(71.39)	-
	(Increase)/decrease to CWIP	-	-
	Advance paid for capital assets	(520.26)	-
	Proceeds From Sales/written off of Fixed Assets	-	-
	<b>Net Cash Flow/(used) in Investing Activities (B)</b>	<b>(612.15)</b>	<b>132.40</b>
<b>C)</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Procurement of Borrowings	32.96	
	Repayment of Borrowings	(1.74)	
	Interest paid	1.34	17.87
	Issue of Shares	1,737.80	-
	<b>Net Cash Flow/(used) From Financing Activities C)</b>	<b>1,770.36</b>	<b>17.87</b>
	<b>Net Increase/(Decrease) in Cash and Cash Equivalent (A+B+C)</b>	<b>599.20</b>	<b>6.61</b>
	Opening balance of Cash and	8.44	1.83

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India  
Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India  
Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIP CODE: 512600, SECURITY ID: MACINTR, BSE India  
Email: meil100@rediffmail.com: Website: <https://www.astal.co.in/>

87





Astal Laboratories Limited

(Formerly known as Macro International Limited)

Cash Equivalent		
<b>Closing balance of Cash and Cash Equivalent</b>	<b>607.63</b>	<b>8.44</b>

The above Cash Flow Statement has been prepared under the indirect Method ' as set out in the Ind AS – 7 "Statement of Cash Flows".

**By order of the Board  
FOR ASTAL LABORATORIES LIMITED**



**SUDHEER KARNA KANKANALA**  
**Whole time Director**  
**DIN: 07591466**

**PLACE: Hyderabad**  
**DATE: 24/05/2024**